

Food and Drug Administration Rockville MD 20857

October 23, 2013

Peter S. Reichertz Sheppard Mullin Richter & Hampton LLP 1300 I Street, NW, 11th Floor East Washington, D.C. 20005-3314

Dear Mr. Reichertz:

Your petition to the Food and Drug Administration on behalf of Luitpold Pharmaceuticals, Inc., requesting the Agency to approve NDAs (or supplements to NDAs) of injectable iron products for treatment of iron deficiency anemia outside of chronic kidney disease, was received by this office on 10/1/2013. It was assigned docket number FDA-2013-P-1294/CP1, and it was filed on 10/23/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Karen Kennard

Director

Division of Dockets Management

Leven Lennord

FDA/Office of the Executive Secretariat (OES)